Community/Retail

The study authors note that the findings could be significant in future HIV vaccine design and development, as well as new approaches to HIV immunotherapy.

The results found that INT301 met both its primary and secondary endpoints and could be a safe and effective option for individuals that experience food allergies.

Individuals received 4 daily short messages that reminding them to participate in self-care, active engagement, and early intervention for the first 30 days of the study.

Investigators aim to find a substitution for incomplete Freund adjuvant, which is not suitable for use in humans but shows a strong response to antigen-specific systemic immune responses.

Language gaps resulted in barriers and underdiagnosing in children with common allergies, limiting support for these patients and their families.

This approval makes birch triterpenes the first treatment for wounds associated with junctional epidermolysis bullosa to be approved by the FDA.

If approved, V116 would offer significant improvements in safety and effectiveness for the prevention of pneumococcal disease.

Previously, garadacimab was granted an orphan drug designation as a therapy for hereditary angioedema by both the FDA and EMA.

Less than 1% of individuals developed Clostridioides difficile infection (CDI), but for those who previously had a CDI the year before, 12% developed a new infection.

The antibody response among those that interrupted treatment was doubled at 4 weeks and 1.5 times greater at 26 weeks.

Treatment options can be limited for this patient population.

Rosemary Sassic-Mihalko, PharmD, is the fourth owner and first female owner of pittsburgh’s oldest pharmacy

Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, discusses the dynamic landscape of the biosimilars market, providing key insights into its current status and future projections.

Using information from clinical studies and her experiences working in the field, Stephanie Kirk describes treatment options that are on the horizon, and how removing stigma is key in HIV care.

The most recent advances included an approved vaccine that could immunize both the elderly and pregnant women, along with the release of nirsevimab.

Older individuals and individuals that experienced severe COVID-19 are at high risk of increased cardiac disturbances.

Unsuccessful arguments at trial court level are upheld on appeal

Investigators analyzed the effects of harmful accumulation of HDAC6 in the brains of mouse models with Alzheimer disease to determine any changes in disease progression.

Although treatment is effective, AEs remain difficult for patients.

Moderate cycling improved cognitive function in patients who got partial or no sleep.

Stress usually occurs as a byproduct of workplace powerlessness because feelings of powerlessness at work prevent us from being the kind of human beings we need to be.

This month's Pharmacy Times Condition Watch features obesity and type 2 diabetes.

The proposed Vaccine Injury Compensation Modernization Act is intended to bring valuable updates to the 36-year-old legislation.

This is the first FDA approval for a therapy intended to reduce the risk of relapse in patients with high-risk neuroblastoma.

Collaboration and knowledge sharing amongst rare disease researchers can be difficult, as these researchers are often spread out throughout the world.

The update also removed the maximally tolerated qualifier for statin use and the statement that said morbidity and mortality was not yet determined.

In the pharmacy, time is the ultimate value-add.

The results found that the M2e nanoparticle injection could efficiently protect individuals from influenza A viruses.

The products include Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution, Icatibant Injection, Esomeprazole Magnesium Capsules, and Apremilast Tablets.

The approval carries the limitation that ritlecitinib should not be used in combination with biologic immunomodulators, cyclosporine, other Janus kinase inhibitors, or other potent immunosuppressants.